Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vera Therapeutics (Nasdaq: VERA) announced inducement awards granted to seven new employees on October 2, 2024. The awards, approved by the Compensation Committee under Nasdaq Listing Rule 5635(c)(4), include:
1. Non-qualified stock options to purchase 125,000 shares of Class A common stock
2. Restricted stock units (RSUs) for 62,500 shares of Class A common stock
The stock options have an exercise price of $41.75 per share, equal to Vera's closing price on October 2, 2024. They will vest over four years, with 25% vesting on the first anniversary and the remainder monthly over 36 months. The RSUs will vest over four years, with 25% vesting annually starting November 20, 2024. Both awards are subject to continued employment and the terms of the Inducement Plan and applicable award agreements.
Vera Therapeutics (Nasdaq: VERA) ha annunciato premi di indennità concessi a sette nuovi dipendenti il 2 ottobre 2024. I premi, approvati dal Comitato per la Remunerazione ai sensi della Regola di Quotazione Nasdaq 5635(c)(4), comprendono:
1. Opzioni su azioni non qualificate per l'acquisto di 125.000 azioni di Class A
2. Unità di azioni vincolate (RSU) per 62.500 azioni di Class A
Le opzioni su azioni hanno un prezzo di esercizio di $41.75 per azione, pari al prezzo di chiusura di Vera del 2 ottobre 2024. Queste si matureranno nel corso di quattro anni, con il 25% che matura al primo anniversario e il restante mensilmente per 36 mesi. Le RSU si matureranno nel corso di quattro anni, con il 25% che matura annualmente a partire dal 20 novembre 2024. Entrambi i premi sono soggetti a un'occupazione continuativa e ai termini del Piano di Indennità e degli accordi relativi ai premi applicabili.
Vera Therapeutics (Nasdaq: VERA) anunció premios de incentivos otorgados a siete nuevos empleados el 2 de octubre de 2024. Los premios, aprobados por el Comité de Compensación bajo la Regla de Listado de Nasdaq 5635(c)(4), incluyen:
1. Opciones sobre acciones no calificadas para adquirir 125,000 acciones de Clase A
2. Unidades de acciones restringidas (RSUs) por 62,500 acciones de Clase A
Las opciones sobre acciones tienen un precio de ejercicio de $41.75 por acción, igual al precio de cierre de Vera el 2 de octubre de 2024. Estas se adquirirán durante cuatro años, con el 25% adquiriéndose en el primer aniversario y el resto mensualmente durante 36 meses. Las RSUs se adquirirán durante cuatro años, con el 25% adquiriéndose anualmente comenzando el 20 de noviembre de 2024. Ambos premios están sujetos a empleo continuo y a los términos del Plan de Incentivos y los acuerdos de premios aplicables.
베라 테라퓨틱스(Vera Therapeutics, Nasdaq: VERA)는 2024년 10월 2일에 새로 채용된 직원 7명에게 유인 보상을 발표했습니다. 이 보상은 나스닥 상장규정 5635(c)(4) 아래 보상위원회에서 승인된 것으로, 내용은 다음과 같습니다:
1. 클래스 A 보통주 125,000주를 구입할 수 있는 비자격 주식 옵션
2. 클래스 A 보통주 62,500주에 대한 제한 주식 단위(RSU)
주식 옵션의 행사가격은 $41.75로, 2024년 10월 2일 베라의 종가와 같습니다. 이 옵션은 4년 동안 매년 25%씩, 첫 번째 기념일에 25%가 취득되고 나머지는 36개월에 걸쳐 매월 취득됩니다. RSU는 4년 동안 매년 25%가 2024년 11월 20일부터 시작하여 취득됩니다. 두 가지 보상 모두 지속적인 고용과 유인 계획 및 적용 가능한 보상 계약의 조건에 따라야 합니다.
Vera Therapeutics (Nasdaq: VERA) a annoncé des primes d'incitation accordées à sept nouveaux employés le 2 octobre 2024. Les primes, approuvées par le comité de rémunération conformément à la règle de cotation Nasdaq 5635(c)(4), comprennent :
1. Options d'achat d'actions non qualifiées pour l'acquisition de 125 000 actions ordinaires de classe A
2. Unités d'actions restreintes (RSUs) pour 62 500 actions ordinaires de classe A
Les options d'achat d'actions ont un prix d'exercice de $41.75 par action, égal au prix de clôture de Vera du 2 octobre 2024. Elles deviendront pleinement acquises sur une période de quatre ans, avec 25% devenant acquis lors du premier anniversaire et le reste mensuellement sur 36 mois. Les RSUs deviendront entièrement acquises sur une période de quatre ans, avec 25% devenant acquis annuellement à partir du 20 novembre 2024. Les deux primes sont soumises à un emploi continu et aux termes du Plan d'Incentive et des accords de primes applicables.
Vera Therapeutics (Nasdaq: VERA) gab am 2. Oktober 2024 Bekanntgabe von Anreizprämien, die an sieben neue Mitarbeiter vergeben wurden. Die Prämien wurden vom Vergütungsausschuss gemäß der Nasdaq-Listingregel 5635(c)(4) genehmigt und umfassen:
1. Nicht qualifizierte Aktienoptionen zum Erwerb von 125.000 Stammaktien der Klasse A
2. Eingeschränkte Aktieneinheiten (RSUs) für 62.500 Stammaktien der Klasse A
Die Aktienoptionen haben einen Ausübungspreis von $41.75 pro Aktie, was dem Schlusskurs von Vera am 2. Oktober 2024 entspricht. Sie werden über einen Zeitraum von vier Jahren fällig, wobei 25% am ersten Jahrestag und der Rest monatlich über 36 Monate fällig wird. Die RSUs werden über vier Jahre fällig, wobei 25% jährlich ab dem 20. November 2024 fällig werden. Beide Prämien sind an die Fortführung der Beschäftigung und die Bedingungen des Anreizplans sowie die geltenden Prämienvereinbarungen gebunden.
- Vera Therapeutics is attracting new talent with stock-based compensation
- The company's stock price was $41.75 on October 2, 2024
- Potential dilution of existing shareholders due to new stock options and RSUs
BRISBANE, Calif., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on October 2, 2024, the Compensation Committee granted inducement awards consisting of a non-qualified stock option to purchase 125,000 shares of Class A common stock and restricted stock units (RSUs) for 62,500 shares of Class A common stock to seven new employees under the Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock option granted on October 2, 2024 has an exercise price per share equal to
About Vera
Vera Therapeutics is a late clinical-stage biotechnology company focused on developing treatments for serious immunological diseases. Vera’s mission is to advance treatments that target the source of immunological diseases in order to change the standard of care for patients. Vera’s lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B-cell Activating Factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases, including IgAN, also known as Berger’s disease, and lupus nephritis. In addition, Vera is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful. Vera is also developing MAU868, a monoclonal antibody designed to neutralize infection with BK virus (BKV), a polyomavirus that can have devastating consequences in certain settings such as kidney transplant. Vera retains all global developmental and commercial rights to atacicept and MAU868. For more information, please visit www.veratx.com.
For more information, please contact:
Investor Contact:
Joyce Allaire
LifeSci Advisors
212-915-2569
jallaire@lifesciadvisors.com
Media Contact:
Madelin Hawtin
LifeSci Communications
MHawtin@lifescicomms.com
FAQ
What inducement awards did Vera Therapeutics (VERA) grant to new employees on October 2, 2024?
What is the exercise price of the stock options granted by Vera Therapeutics (VERA) on October 2, 2024?
How will the stock options and RSUs granted by Vera Therapeutics (VERA) vest?
